TLR3 and neoplasm: For example, intravaginal administration of TLR3 and/or TLR9 agonists following subcutaneous immunization with HPV E7 antigen lead to about fivefold increase in the level of INF-gamma-producing CD8 T cells homing to the vaginal mucosa with a threefold higher level of tumour regression of HPV16 tumour compared to only subcutaneous immunization in mice116.